Phreesia, Inc. (NYSE:PHR) SVP David Linetsky Sells 11,853 Shares

Phreesia, Inc. (NYSE:PHR) SVP David Linetsky sold 11,853 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $24.85, for a total value of $294,547.05. Following the completion of the transaction, the senior vice president now directly owns 188,354 shares in the company, valued at approximately $4,680,596.90. This trade represents a 5.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

David Linetsky also recently made the following trade(s):

• On Friday, October 18th, David Linetsky sold 1,100 shares of Phreesia stock. The stock was sold at an average price of $20.49, for a total value of $22,539.00.
• On Tuesday, October 15th, David Linetsky sold 2,011 shares of Phreesia stock. The shares were sold at an average price of $21.03, for a total value of $42,291.33.
• On Thursday, September 19th, David Linetsky sold 24 shares of Phreesia stock. The stock was sold at an average price of $24.04, for a total transaction of $576.96.
• On Tuesday, September 17th, David Linetsky sold 36 shares of Phreesia stock. The shares were sold at an average price of $24.77, for a total transaction of $891.72.

Phreesia Trading Up 1.6 %

Shares of NYSE:PHR opened at $24.94 on Monday. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $29.16. The company has a current ratio of 1.74, a quick ratio of 1.77 and a debt-to-equity ratio of 0.04. The company’s 50 day moving average is $20.45 and its 200 day moving average is $21.81.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The firm had revenue of $106.80 million for the quarter, compared to analyst estimates of $106.33 million. During the same quarter in the prior year, the business earned ($0.58) earnings per share. The business’s quarterly revenue was up 16.6% compared to the same quarter last year. Analysts expect that Phreesia, Inc. will post -1.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Phreesia

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Trust Point Inc. boosted its stake in shares of Phreesia by 3.5% in the third quarter. Trust Point Inc. now owns 17,887 shares of the company’s stock worth $408,000 after buying an additional 607 shares during the last quarter. Ensign Peak Advisors Inc boosted its position in Phreesia by 3.2% in the 2nd quarter. Ensign Peak Advisors Inc now owns 22,491 shares of the company’s stock worth $477,000 after purchasing an additional 700 shares in the last quarter. Rhumbline Advisers boosted its position in Phreesia by 1.0% in the 2nd quarter. Rhumbline Advisers now owns 82,136 shares of the company’s stock worth $1,741,000 after purchasing an additional 853 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Phreesia by 3.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company’s stock valued at $637,000 after purchasing an additional 905 shares in the last quarter. Finally, MetLife Investment Management LLC increased its holdings in shares of Phreesia by 3.8% during the 3rd quarter. MetLife Investment Management LLC now owns 30,781 shares of the company’s stock valued at $701,000 after purchasing an additional 1,120 shares in the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PHR. Robert W. Baird reduced their price target on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 target price on shares of Phreesia in a research report on Tuesday, December 10th. DA Davidson reiterated a “buy” rating and issued a $32.00 price target on shares of Phreesia in a research note on Thursday, September 5th. JPMorgan Chase & Co. boosted their price target on Phreesia from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Monday, September 9th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $23.00 price objective on shares of Phreesia in a research report on Friday, September 27th. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, Phreesia currently has a consensus rating of “Moderate Buy” and an average target price of $29.33.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.